USPTO serial 79403126
HUGEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 19, 2025
- Examiner
- MASON, JARED MICHAEL
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HUGEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James R Menker
James R Menker Holley & Menker, PAPO Box 331937Atlantic Beach, FL 32233United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Chemical reagents for pharmaceutical purposes; chemical preparations for pharmaceutical purposes for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis and cerebral palsy; chemical preparations for pharmaceutical purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; chemical preparations for pharmaceutical purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; chemical preparations for pharmaceutical purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labor pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical agents for epidermis; antibiotic ointments for pharmaceutical purposes; anti-itch ointments for pharmaceutical purposes; dermatology ointments for pharmaceutical purposes; medicated ointments for treating dermatological conditions; preparations of microorganisms for medical or veterinary use; adjuvants for medical purposes; appetite suppressants for medical purposes; drugs for medical purposes, namely, pain relief medications; drugs for medical purposes for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis and cerebral palsy; drugs for medical purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; drugs for medical purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; drugs for medical purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labor pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; dermatological pharmaceutical products; pharmaceutical preparations for skin care; medicated hair lotions; medicated lotions for skin, hair, sunburn, face, body and hands; medicated lotions for treating dermatological conditions; pharmaceutical skin lotions; medical oral care gels for activation of tissues; medical topical gels for activation of skin tissues; hyaluronic acid preparations for medical purposes; medicines for human purposes being antivirals; medicines for human purposes for treating dermatological conditions; medicines for human purpose, namely, medicines for skin care; medicines for human purposes, namely, medicinal preparations for the mouth to be applied in the form of drops, capsules, tablets and compressed tablets; medicines for human purposes for the treatment of cardiovascular and cerebrovascular diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of spasm; pharmaceutical preparations for treating dystonia; pharmaceutical products for skin care for animals; pharmaceutical preparations used in cosmetic surgery; pharmaceutical preparations for use in treating urogenital system diseases and conditions, namely, overactive bladder and urinary incontinence; pharmaceutical preparations for digestive system; pharmacological preparations for skin care; pharmaceutical preparations for treating peripheral neurological diseases and disorders; pharmaceutical preparations for treating central neurological diseases and disorders; pharmaceutical preparations for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for the treatment of orthopedic disorders, namely, hip dislocation, spinal column deformation, curvature of the spine, namely, scoliosis, lordosis, kyphosis; pharmaceutical preparations for smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, tremors and pain; pharmaceutical preparations for the treatment of wrinkles; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations mainly based on hyaluronic acid for treatments, namely, injectable for intradermal and subcutaneous application for facial and body skin tightening and smoothing; injectable dermal fillers; air deodorizing preparations; mothproof paper; pharmaceutical preparations being antivirals containing botulinum toxin; pharmaceutical preparations containing botulinum toxin for the treatment of wrinkles; pharmaceutical preparations containing botulinum toxin fragments for the treatment of wrinkles; surgical implants comprised of living tissues; bacterial toxins for medical purposes, namely, botulinum toxin for medical use for use in the treatment of excessive sweating; botulinum toxin for the treatment of facial wrinkles; botulinum toxin for medical use for use in the treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, headache, pain, spasm, dystonia, urogenital system diseases and conditions, skin disorders; bacterial poisons; food for babies; biological preparations for the treatment of cancer; biological preparations for medical purposes for the treatment of aesthetic dermatology, orthopedics, arthritis and ophthalmology; biological preparations for medical purposes for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhidrosis and cerebral palsy; biological preparations for medical purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; biological preparations for veterinary purposes for the treatment of aesthetic dermatology, orthopedics, arthritis and ophthalmology; bacterial preparations for medical purposes; bacterial preparations for veterinary use; chemical reagents for medical or veterinary purposes; pre-filled syringes for medical purposes filled with pain relief medication; pre-filled syringes for medical purposes containing saline for rehydrating the skin, pharmaceuticals for dissolving skin wrinkles; pre-filled self injection syringes for medical purposes for injection of prefilled hyaluronic acid; medicinal creams for skin care; medicated cleansers for skin and wounds; medicated moisturizing creams; nutritional supplements; protein dietary supplements; disposable baby diapers; disposable diapers for pets; composite materials for dental and dental technical purposes; skin grafts; medicated skin care preparations; implants comprising living tissue for use in guided tissue regeneration; pharmaceuticals in the nature of sports cream for relief of pain, analgesics, anti-inflammatories, cough syrups, pain relief medication, fungal medications, antiseptics, cold sore treatment preparations, allergy medications, decongestants, vitamin and mineral supplements, acne medications, muscle relaxants, anti-itch cream, medicated candies, medicated bath preparations, medicated beauty soap, medicated confectionery, eye drops, dermatologicals; gastrodia elata for pharmaceutical purposes; medical X-ray contrast agents; oxygen for medical purposes; chemical conductors for electrocardiograph electrodes; semen for artificial insemination; disinfectants for hygiene purposes; contact lens cleaning preparations; chewing gum for medical purposes; biological herbicides; bandages for dressings | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 19, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 3, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 3, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 12, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 27, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 19, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 19, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 19, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 3, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 3, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 28, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 1, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 9, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 8, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 8, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 21, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 17, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 24, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 23, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 6, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 6, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 29, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |